Replimune Group, Inc.
NASDAQ:REPLBiotechnology
Healthcare
$19.23 +1.85%
+$0.19 today
- Market cap
- $1.82B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
52W Low $1.50High $13.24
Volume 1.69M
Average 7.51M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$261.63M
FY 2025 · Annual
Net Income
-$247.30M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.14M | 4.58M | 0 | 0 | 0 |
| Gross Profit | (4.14M) | (4.58M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 57.49M | 80.65M | 126.53M | 174.96M | 189.45M |
| Selling, General & Admin | 21.13M | 36.26M | 0 | 0 | 0 |
| Operating Expenses | 78.62M | 116.91M | 177.08M | 234.77M | 261.63M |
| Depreciation & Amortization | 4.14M | 4.58M | 2.45M | 5.08M | 5.93M |
| EBITDA | (76.48M) | (114.41M) | (171.72M) | (227.77M) | (253.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (82.76M) | (121.48M) | (177.08M) | (234.77M) | (261.63M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 916K | 390K | 10.01M | 23.36M | 21.12M |
| Interest Expense | 3.06M | 2.22M | 4.16M | 6.66M | 7.89M |
| Other Income / Expenses | (915K) | 278K | 3.08M | 19.39M | 14.8M |
| Income Before Tax | (83.68M) | (121.21M) | (174M) | (215.39M) | (246.83M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.81M) | (3.17M) | 288K | 408K | 468K |
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| EPS (Diluted) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| 46.25M | 52.21M | 58.21M | 66.57M | 80.56M | |
| 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
REPL Earnings Waterfall · TTM
NASDAQ:REPL · Revenue to Net Income
Key Ratios
EPS$-3.58
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$314.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.58, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 9, 2026 | |
| 10-Q/A | 10-Q/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much revenue does REPL generate?
Replimune Group, Inc. (REPL) reported $0.00 of revenue in fiscal 2025.
Is REPL profitable?
Replimune Group, Inc. (REPL) reported -$247.30M of net income.
Continue the stock analysis
Jump to another research area for this company.